Holen Sie sich die Stockscreener-App
13.45
1.10%
-0.15
Handel nachbörslich:
13.45
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$13.60
Offen:
$13.59
24-Stunden-Volumen:
2.18M
Relative Volume:
0.87
Marktkapitalisierung:
$11.20B
Einnahmen:
$3.97B
Nettoeinkommen (Verlust:
$644.90M
KGV:
17.26
EPS:
0.7794
Netto-Cashflow:
$90.19M
1W Leistung:
+7.95%
1M Leistung:
+1.13%
6M Leistung:
-4.27%
1J Leistung:
-6.98%
1-Tages-Spanne:
$13.45
$13.60
1-Wochen-Bereich:
$12.74
$13.89
52-Wochen-Spanne:
$12.19
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.45 | 11.32B | 3.97B | 644.90M | 90.19M | 0.7794 |
TAK
Takeda Pharmaceutical Co Adr
|
16.58 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.20 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.92 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
566.80 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-23 | Herabstufung | Goldman | Neutral → Sell |
| 2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations - Investing.com UK
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Sahm
Dr. Reddy's Laboratories Ltd stock (INE089A01023): earnings miss and dual-market focus draw attentio - AD HOC NEWS
Dr. Reddy's Laboratories stock: Earnings miss shapes outlook - AD HOC NEWS
Dr. Reddy’s Labs ADR earnings missed by $0.05, revenue fell short of estimates - Investing.com
Dr. Reddy's Earnings: Lenalidomide's Slide Digs Into Numbers, but Base Business Remains Solid - Morningstar
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast - Investing.com
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast By Investing.com - Investing.com Australia
Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS
Dr. Reddy’s (NYSE: RDY) approves new ESOP and ADR stock option grants - Stock Titan
Dr. Reddy's Grants Employee Stock Options, Raising Dilution Concerns - Whalesbook
Dr. Reddy’s Laboratories grants over 1.19 million stock options to employees - Business Upturn
RDY Stock Price, Quote & Chart | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Laboratories Ltd. Sponsored ADR Trade Ideas — LS:659157 - TradingView
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada - ChartMill
Earnings BeforeStock ScreenerSnapshot - Finviz
Dr. Reddy's on Pace for Largest Percent Increase Since June 2025 — Data Talk - Morningstar
Dr. Reddy's Labs (ADR) stock (US2565981035): Why Google Discover changes matter more now - AD HOC NEWS
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - MSN
Dr Reddy’s (NYSE: RDY) Europe head reports 8,450 ADR-backed shares - Stock Titan
Dr. Reddy’s (NYSE: RDY) North America CEO reports 47,325 ADR shares - Stock Titan
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 3,675 Equity Shares Under Employee Stock Option Plan - scanx.trade
Employee stock options add 3,675 Dr. Reddy’s (NYSE: RDY) shares - Stock Titan
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Benzinga
Dr. Reddy's Laboratories Ltd Stock Faces Analyst Downgrade Despite Strong Valuation—What European - AD HOC NEWS
Sapient Quality Select ETF Holdings - Quiver Quantitative
Dr. Reddy’s Allots New ESOP Shares, Slightly Increases Equity Capital - TipRanks
Dr. Reddy’s (NYSE: RDY) allots 10,275 ESOP shares to employees - Stock Titan
Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement - scanx.trade
Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme - scanx.trade
Dr. Reddy’s Laboratories issues 10,275 equity shares under stock options scheme - Business Upturn
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
Mercurity Fintech Holding Inc ADR share price - Mint
Mitsubishi UFJ Financial Group Inc ADR share price - Mint
3 Generic Drug Stocks to Watch Despite Industry Headwinds - The Globe and Mail
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy - ChartMill
Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action - scanx.trade
Dr. Reddy’s Stock Pops on US Launch Momentum: Buy the Breakout? - AD HOC NEWS
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes - scanx.trade
Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital - TipRanks
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test - ChartMill
US-India Trade Deal: Indian ADRs Jump Up To 6.75%; Sensex & Nifty Set For Rally - samco.in
Dr. Reddy’s Labs ADR earnings beat by $14.36, revenue topped estimates - Investing.com Australia
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y - Finviz
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):